What is norvasc for
Pro Research Analysisby 
Searched over 200M research papers
Understanding the Uses of Norvasc
Norvasc for Hypertension Management
Norvasc, also known by its generic name amlodipine, is primarily used for the management of hypertension (high blood pressure). Research has shown that Norvasc is effective in controlling blood pressure and reducing the risk of cardiovascular and cerebrovascular complications in patients with hypertension. In a study involving patients with second-grade hypertension, Norvasc demonstrated a high efficacy rate of 93.3% in stabilizing blood pressure, significantly outperforming Nifedipine, another antihypertensive medication2.
Norvasc in Reducing Cardiovascular Events
Norvasc is also beneficial in reducing the incidence of cardiovascular events (CVE) such as coronary heart disease (CHD) and stroke. A comparative study between Norvasc and Exforge (a combination of amlodipine and valsartan) revealed that while Exforge had superior outcomes, Norvasc still significantly reduced the incidence of CHD and stroke over a 10-year period. Specifically, Norvasc reduced the incidence of CHD by 29.74% and stroke by 37.91% in patients with varying levels of risk factors3.
Norvasc and Coronary Atherosclerosis
Another important use of Norvasc is in the management of coronary atherosclerosis. The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was designed to assess whether Norvasc could slow or reverse the progression of early coronary atherosclerosis in patients with documented disease. This trial also included carotid ultrasound examinations to correlate disease progression in different arterial beds, providing a comprehensive understanding of Norvasc's vascular effects1.
Conclusion
Norvasc is a versatile medication primarily used for managing hypertension and reducing the risk of cardiovascular events. It has shown significant efficacy in stabilizing blood pressure and reducing the incidence of CHD and stroke. Additionally, Norvasc may play a role in managing coronary atherosclerosis, making it a valuable option in cardiovascular disease management.
Sources and full results
Most relevant research papers on this topic
Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
The PREVENT trial aims to determine if Norvasc can slow or reverse early coronary atherosclerosis progression in patients with documented disease.
The Effect of Norvasc on Ambulatory Blood Pressure and Compliction of the Patients with Hypertension
Norvasc effectively controls blood pressure and reduces cardiovascular and cerebrovascular complications in patients with hypertension.
Observational Studye0584 A study of Exforge on the treatment effects and CVE prevention in patients with mild to moderate essential hypertension
Exforge is a better treatment for mild to moderate essential hypertension and reduces the incidence of cardiovascular events more effectively than Norvasc.
RCT
Rigorous JournalIt's time medicine stopped burying its mistakes.
NORVASC is a safe and effective oral calcium channel blocker for patients with heart failure, but caution is advised when using it with other medications.
Comparative study of Yashida and Norvasc in chronic renal insufficiency with hypertension
Yashida 5mg or 10mg daily is as effective and safe as Novasc in treating hypertension in chronic renal insufficiency patients.
RCTCoronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
Norvasc reduces clinical events, such as hospitalization for unstable angina pectoris and the need for percutaneous coronary interventions, in patients with minimal angiographic disease.
[Efficacy of adipin and normodipin (generic drugs of amlodipine) vs norvsc in treatment of essential hypertension].
Generic drugs adipin and normodipine are as effective and safe as original norvasc in treating essential hypertension.
Observational StudyChronic Conjunctival Chemosis From Amlodipine Besylate (Norvasc)
Amlodipine besylate (Norvasc) may cause conjunctival chemosis and bipedal edema in the eye, with resolution 6 months after discontinuing the medication.
Case ReportOverview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
Amlodipine reduces carotid intima-media thickness progression and significantly reduces unstable angina hospital admissions, but does not affect minor coronary lesions.
Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.
Lipid-lowering therapy is underutilized in patients with coronary artery disease, particularly in women, suggesting a need for more intensive efforts to maximize CAD reduction.
RCT
Large Human Trial
Highly Cited